NCT05984953View on ClinicalTrials.gov

Rosuvastatin and Evolocumab for Coronary Artery Disease

CompletedOBSERVATIONAL
Enrollment

195

Participants

Timeline

Start Date

August 1, 2013

Primary Completion Date

October 28, 2022

Study Completion Date

October 28, 2022

Conditions
Coronary Artery Disease
Interventions
DRUG

statin

40 mg of rosuvastatin daily for 8-12 weeks

DRUG

evolocumab

140 mg evolocumab every 2 weeks (26 weeks)

Trial Locations (1)

10029

Mount Sinai Hospital, New York

All Listed Sponsors
lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT05984953 - Rosuvastatin and Evolocumab for Coronary Artery Disease | Biotech Hunter | Biotech Hunter